We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of CRISPR THERAPTC (CRSP - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CRISPR THERAPTC is a member of the Medical sector. This group includes 763 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for CRSP's full-year earnings has moved 7.81% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, CRSP has returned 150.38% so far this year. Meanwhile, stocks in the Medical group have lost about 0.14% on average. As we can see, CRISPR THERAPTC is performing better than its sector in the calendar year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 282 individual stocks and currently sits at #154 in the Zacks Industry Rank. On average, stocks in this group have lost 5.81% this year, meaning that CRSP is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CRSP as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of CRISPR THERAPTC (CRSP - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
CRISPR THERAPTC is a member of the Medical sector. This group includes 763 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CRSP is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for CRSP's full-year earnings has moved 7.81% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, CRSP has returned 150.38% so far this year. Meanwhile, stocks in the Medical group have lost about 0.14% on average. As we can see, CRISPR THERAPTC is performing better than its sector in the calendar year.
Looking more specifically, CRSP belongs to the Medical - Biomedical and Genetics industry, which includes 282 individual stocks and currently sits at #154 in the Zacks Industry Rank. On average, stocks in this group have lost 5.81% this year, meaning that CRSP is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CRSP as it looks to continue its solid performance.